Marburg virus reaches Rwanda: how close are we to a vaccine solution?

IF 4.8 2区医学 Q1 INFECTIOUS DISEASES

International Journal of Infectious Diseases Pub Date : 2024-12-19 DOI:10.1016/j.ijid.2024.107371

Olivier Sibomana , Clyde Moono Hakayuwa , Jildas Munyantore

{"title":"Marburg virus reaches Rwanda: how close are we to a vaccine solution?","authors":"Olivier Sibomana , Clyde Moono Hakayuwa , Jildas Munyantore","doi":"10.1016/j.ijid.2024.107371","DOIUrl":null,"url":null,"abstract":"<div><div>Marburg virus disease (MVD) is a highly virulent and often fatal disease caused by the Marburg virus, a member of the <em>Filoviridae</em> family, closely related to the Ebola virus. Historically, outbreaks have been sporadic but lethal across various African countries, with high case fatality rates (CFRs). In 2023, significant outbreaks occurred in Tanzania and Equatorial Guinea, with CFRs of 62.5% and 75%, respectively. In 2024, Rwanda faced its first outbreak, starting on September 27, 2024. By November 8, 2024, Rwanda had conducted 7,408 tests, confirming 66 cases, 15 of which were fatal, and 51 recoveries. Although no approved vaccine currently exists for MVD, global health authorities are prioritizing the development of effective vaccines. Drawing on insights from the rapid COVID-19 vaccine development, several promising candidates are under exploration, with the cAd3-MARV showing notable potential. This paper examines the current MVD outbreak in Rwanda and the progress toward developing a long-term vaccine solution.</div></div>","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":"153 ","pages":"Article 107371"},"PeriodicalIF":4.8000,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1201971224004466","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Marburg virus disease (MVD) is a highly virulent and often fatal disease caused by the Marburg virus, a member of the Filoviridae family, closely related to the Ebola virus. Historically, outbreaks have been sporadic but lethal across various African countries, with high case fatality rates (CFRs). In 2023, significant outbreaks occurred in Tanzania and Equatorial Guinea, with CFRs of 62.5% and 75%, respectively. In 2024, Rwanda faced its first outbreak, starting on September 27, 2024. By November 8, 2024, Rwanda had conducted 7,408 tests, confirming 66 cases, 15 of which were fatal, and 51 recoveries. Although no approved vaccine currently exists for MVD, global health authorities are prioritizing the development of effective vaccines. Drawing on insights from the rapid COVID-19 vaccine development, several promising candidates are under exploration, with the cAd3-MARV showing notable potential. This paper examines the current MVD outbreak in Rwanda and the progress toward developing a long-term vaccine solution.

查看原文本刊更多论文

马尔堡病毒到达卢旺达：我们离疫苗解决方案还有多远？

马尔堡病毒病是由与埃博拉病毒密切相关的丝状病毒科成员马尔堡病毒引起的一种高毒力且往往致命的疾病。从历史上看，疫情是零星的，但在非洲各国是致命的，病死率很高。2023年，坦桑尼亚和赤道几内亚发生了重大疫情，病死率分别为62.5%和75%。2024年，卢旺达从9月27日开始面临第一次疫情。截至2024年11月8日，卢旺达共进行了7408次检测，确诊66例，其中15例死亡，51例康复。虽然目前没有批准的MVD疫苗，但全球卫生当局正在优先考虑开发有效疫苗。根据快速开发COVID-19疫苗的经验，目前正在探索几种有希望的候选疫苗，其中cAd3-MARV显示出显着的潜力。本文审查了卢旺达目前的MVD暴发以及在制定长期疫苗解决方案方面取得的进展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Infectious Diseases 医学-传染病学

CiteScore

18.90

自引率

2.40%

发文量

1020

审稿时长

30 days

期刊介绍： International Journal of Infectious Diseases (IJID) Publisher: International Society for Infectious Diseases Publication Frequency: Monthly Type: Peer-reviewed, Open Access Scope: Publishes original clinical and laboratory-based research. Reports clinical trials, reviews, and some case reports. Focuses on epidemiology, clinical diagnosis, treatment, and control of infectious diseases. Emphasizes diseases common in under-resourced countries.